Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI
patients. The investigators propose to evaluate the clinical efficacy and safety of
anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of
anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI
(primary hypothesis). When allocated to anticoagulation prolongation by randomization, the
subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre)
for at least 48 hours after PPCI. The results from this study are expected to provide
guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Anzhen Hospital
Collaborators:
ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France Chinese Academy of Medical Sciences, Fuwai Hospital